US and UK Strike Tariff-Free Arrangement on Pharmaceuticals.
The UK and US have secured a landmark commercial pact that will ensure zero levies on UK pharmaceutical exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to increase spending on medicines through the public health system. This pledge secures that import taxes on these crucial products will stay at nothing for a timeframe of three years.
This agreement is in response to previous warnings to significantly raise duties on branded pharmaceutical imports, with figures discussed reaching 100%.
"This agreement with the Britain reinforces the global environment for cutting-edge drugs and introduces much-needed fairness to American-British medicine commerce," a release noted.
Trade Importance
Drugs constitute one of the Britain's largest exports to the United States, which is by far the primary buyer for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of September, the UK sold medicines valued at billions to the US. This figure accounted for 17.4% of all goods exports in that timeframe.
"This guarantee protects jobs, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. Last year, repayments were more than twenty percent.
Industry Background
The pact takes place against a protracted tension between the pharmaceutical industry and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by arguments that American consumers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been paused or cancelled, while major expansions have been announced toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a share of its overall budget over the last ten years.
